Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TRP009
MIFTS: 41

Triple X Syndrome

Categories: Endocrine diseases, Fetal diseases, Muscle diseases, Nephrological diseases, Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Triple X Syndrome

About this section

MalaCards integrated aliases for Triple X Syndrome:

Name: Triple X Syndrome 74 20 43 58
Xxx Syndrome 20 43 58
Trisomy X 20 43 58
Trisomy X Syndrome 29 71
Triplo X Syndrome 20 43
47,xxx Syndrome 43 58
47,xxx 74 43
Triple-X Chromosome Syndrome 20
Triplo-X Syndrome 58
47 Xxx Syndrome 20
Triple-X Female 20

Characteristics:

Orphanet epidemiological data:

58
trisomy x
Inheritance: Not applicable; Age of onset: Childhood,Infancy; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Rare diseases Fetal diseases
Anatomical: Reproductive diseases Endocrine diseases Nephrological diseases Muscle diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare infertility disorders
Rare gynaecological and obstetric diseases
Rare endocrine diseases
Developmental anomalies during embryogenesis


External Ids:

MESH via Orphanet 45 D014314
ICD10 via Orphanet 33 Q97.0
UMLS via Orphanet 72 C0221033
Orphanet 58 ORPHA3375
UMLS 71 C0221033
Sources

Summaries for Triple X Syndrome

About this section
GARD : 20 47 XXX syndrome, also called trisomy X or triple X syndrome, is characterized by the presence of an additional (third) X chromosome in each of a female's cells (which normally have two X chromosomes). An extra copy of the X chromosome is associated with tall stature, learning problems, and other features in some girls and women. Seizures or kidney abnormalities occur in about 10 percent of affected females. 47 XXX syndrome is usually caused by a random event during the formation of reproductive cells (eggs and sperm). An error in cell division called nondisjunction can result in reproductive cells with an abnormal number of chromosomes. Treatment typically focuses on specific symptoms, if present. Some females with 47 XXX syndrome have an extra X chromosome in only some of their cells; this is called 46,XX/47,XXX mosaicism.

MalaCards based summary : Triple X Syndrome, also known as xxx syndrome, is related to numeric sex chromosome variations and turner syndrome. An important gene associated with Triple X Syndrome is SHOX (Short Stature Homeobox). The drugs Ethanol and Labetalol have been mentioned in the context of this disorder. Affiliated tissues include prostate, skin and kidney, and related phenotypes are abnormality of chromosome segregation and global developmental delay

MedlinePlus Genetics : 43 Triple X syndrome, also called trisomy X or 47,XXX, is characterized by the presence of an additional X chromosome in each of a female's cells. Although females with this condition may be taller than average, this chromosomal change typically causes no unusual physical features. Most females with triple X syndrome have normal sexual development and are able to conceive children.Triple X syndrome is associated with an increased risk of learning disabilities and delayed development of speech and language skills. Delayed development of motor skills (such as sitting and walking), weak muscle tone (hypotonia), and behavioral and emotional difficulties are also possible, but these characteristics vary widely among affected girls and women. Seizures or kidney abnormalities occur in about 10 percent of affected females.

Wikipedia : 74 Triple X syndrome, also known as trisomy X and 47,XXX, is characterized by the presence of an extra X... more...

Sources

Related Diseases for Triple X Syndrome

About this section

Diseases related to Triple X Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 172)
# Related Disease Score Top Affiliating Genes
1 numeric sex chromosome variations 11.2
2 turner syndrome 10.6
3 48, xxxx 10.4
4 48,xyyy 10.4
5 47,xyy 10.4
6 nondisjunction 10.4
7 chromosomal triplication 10.2
8 autoimmune disease 10.2
9 renal hypodysplasia/aplasia 1 10.2
10 hypogonadism 10.2
11 amenorrhea 10.1
12 systemic lupus erythematosus 10.1
13 rett syndrome 10.1
14 patent ductus arteriosus 1 10.1
15 azoospermia 10.1
16 46 xx gonadal dysgenesis 10.1
17 premature menopause 10.1
18 hypertelorism 10.0
19 heart septal defect 10.0
20 cat eye syndrome 9.9
21 coarctation of aorta 9.9
22 cri-du-chat syndrome 9.9
23 attention deficit-hyperactivity disorder 9.9
24 kabuki syndrome 1 9.9
25 otitis media 9.9
26 prader-willi syndrome 9.9
27 sarcoidosis 1 9.9
28 myelofibrosis 9.9
29 scott syndrome 9.9
30 insulin-like growth factor i 9.9
31 taurodontism 9.9
32 muscular dystrophy, duchenne type 9.9
33 orofaciodigital syndrome i 9.9
34 tooth size 9.9
35 46,xx sex reversal 1 9.9
36 chylothorax, congenital 9.9
37 ring chromosome 14 syndrome 9.9
38 cloacal exstrophy 9.9
39 46,xx sex reversal 9.9
40 tonsillitis 9.9
41 intestinal atresia 9.9
42 transsexualism 9.9
43 infant gynecomastia 9.9
44 primary biliary cholangitis 9.9
45 gender identity disorder 9.9
46 pancytopenia 9.9
47 gynecomastia 9.9
48 disorder of sexual development 9.9
49 focal epilepsy 9.9
50 acromegaly 9.9

Graphical network of the top 20 diseases related to Triple X Syndrome:



Diseases related to Triple X Syndrome
Sources

Symptoms & Phenotypes for Triple X Syndrome

About this section

Human phenotypes related to Triple X Syndrome:

58 31 (show all 23)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of chromosome segregation 58 31 hallmark (90%) Very frequent (99-80%) HP:0002916
2 global developmental delay 58 31 frequent (33%) Frequent (79-30%) HP:0001263
3 cognitive impairment 58 31 frequent (33%) Frequent (79-30%) HP:0100543
4 specific learning disability 58 31 frequent (33%) Frequent (79-30%) HP:0001328
5 epicanthus 58 31 frequent (33%) Frequent (79-30%) HP:0000286
6 clinodactyly of the 5th finger 58 31 frequent (33%) Frequent (79-30%) HP:0004209
7 tall stature 58 31 frequent (33%) Frequent (79-30%) HP:0000098
8 hypotonia 31 frequent (33%) HP:0001252
9 depressivity 58 31 occasional (7.5%) Occasional (29-5%) HP:0000716
10 tremor 58 31 occasional (7.5%) Occasional (29-5%) HP:0001337
11 hypertelorism 58 31 occasional (7.5%) Occasional (29-5%) HP:0000316
12 hip dysplasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001385
13 attention deficit hyperactivity disorder 58 31 occasional (7.5%) Occasional (29-5%) HP:0007018
14 anxiety 58 31 occasional (7.5%) Occasional (29-5%) HP:0000739
15 secondary amenorrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0000869
16 pectus excavatum 58 31 occasional (7.5%) Occasional (29-5%) HP:0000767
17 renal hypoplasia/aplasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0008678
18 upslanted palpebral fissure 58 31 occasional (7.5%) Occasional (29-5%) HP:0000582
19 joint hyperflexibility 58 31 occasional (7.5%) Occasional (29-5%) HP:0005692
20 multicystic kidney dysplasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000003
21 seizure 31 occasional (7.5%) HP:0001250
22 seizures 58 Occasional (29-5%)
23 muscular hypotonia 58 Frequent (79-30%)
Sources

Drugs & Therapeutics for Triple X Syndrome

About this section

Drugs for Triple X Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Labetalol Approved Phase 4 36894-69-6 3869
3
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
4
Cetuximab Approved Phase 4 205923-56-4 56842117 2333
5
Fluorouracil Approved Phase 4 51-21-8 3385
6
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
7
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
8
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
9 Neurotransmitter Agents Phase 4
10 Antihypertensive Agents Phase 4
11 Dermatologic Agents Phase 4
12 Adrenergic Agents Phase 4
13 Sympathomimetics Phase 4
14 Hormones Phase 4
15 Gastrointestinal Agents Phase 4
16 Psychotropic Drugs Phase 4
17 Antipsychotic Agents Phase 4
18 Anti-Anxiety Agents Phase 4
19 Trace Elements Phase 4
20 Micronutrients Phase 4
21 Adrenergic alpha-1 Receptor Antagonists Phase 4
22 Adrenergic alpha-Antagonists Phase 4
23 Adrenergic beta-Antagonists Phase 4
24 Adrenergic Antagonists Phase 4
25 Vasodilator Agents Phase 4
26 Vitamins Phase 4
27 Nutrients Phase 4
28 Calciferol Phase 4
29 Hydroxycholecalciferols Phase 4
30 Calcium, Dietary Phase 4
31 Immunosuppressive Agents Phase 4
32 Antibiotics, Antitubercular Phase 4
33 Immunologic Factors Phase 4
34 Anti-Bacterial Agents Phase 4
35 Alkylating Agents Phase 4
36 Antineoplastic Agents, Immunological Phase 4
37 Mitomycins Phase 4
38 Antimetabolites Phase 4
39
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
40
Calcium Nutraceutical Phase 4 7440-70-2 271
41
Azelaic acid Approved Phase 3 123-99-9 2266
42
Eliglustat Approved Phase 3 491833-29-5 23652731
43
Mesna Approved, Investigational Phase 3 3375-50-6 598
44
Etoposide Approved Phase 3 33419-42-0 36462
45
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
46
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
47
Lenograstim Approved, Investigational Phase 3 135968-09-1
48
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
49
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
50
Ifosfamide Approved Phase 3 3778-73-2 3690

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 A Phase IV Open, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of a Pediatric Presentation (0.25 ml) of the Virosomal Hepatitis A Virus (HAV) Vaccine HAVpur in Healthy Young Children Aged Between and Including 18 Months to 47 Months, Using a 0/6 Month Immunization Schedule Completed NCT01349829 Phase 4
2 Nasally Inhaled Isopropyl Alcohol Versus Oral Ondansetron for the Treatment of Nausea in the Emergency Department: A Double-Blind Randomized Controlled Trial Completed NCT02760069 Phase 4 Inhaled isopropyl alcohol;Oral ondansetron;Inhaled normal saline;Oral placebo
3 Effects of Nitroglycerin Versus Labetalol on Tissue Perfusion During Deliberate Hypotension for Sinus Endoscopic Surgery. Completed NCT03809065 Phase 4 Nitroglycerin;Labetalol
4 Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS Completed NCT03644212 Phase 4 Vitamin D3
5 Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Terminated NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
6 A Multicenter, Randomized, Controlled, Double-masked, Crossover Design Study to Compare Efficacy and Assess Safety of CD07805/47 Gel 0.5% Applied Once Daily vs Azelaic Acid Gel 15% Applied Twice Daily in Subjects With Erythema of Rosacea Completed NCT01659853 Phase 3 CD07805/47 gel 0.5%/CD07805/47 Vehicle;azelaic acid gel 15%
7 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients With Gaucher Disease Type 1 (ENGAGE) Completed NCT00891202 Phase 3 Eliglustat tartrate;Placebo
8 Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma Completed NCT00354744 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;irinotecan hydrochloride;vincristine sulfate
9 A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01355471 Phase 3 CD07805/47 Gel;Placebo
10 A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01355458 Phase 3 CD07805/47 gel;Placebo
11 A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01318733 Phase 3 CD07805/47 gel 0.5%
12 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea Completed NCT01789775 Phase 3 Drug: CD07805/47 gel;CD07805/47 gel Placebo
13 A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) and a United States Licensed Quadrivalent Influenza Virus Vaccine (QIV) in Healthy Subjects 6 Months Through 47 Months Completed NCT04074928 Phase 3
14 A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer Completed NCT00171704 Phase 3 Letrozole;Tamoxifen
15 Randomised, Controlled Clinical Study Regarding the Feasibility of Converting Opiate Dependents From Methadone Substitutes to Slow Release Morphine Sulphate (Sevre-Longâ„¢) Completed NCT01079117 Phase 3 Sevre-Longâ„¢;Slow release oral morphine;Methadone
16 A Phase 3, Long-Term, Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects Completed NCT02610868 Phase 3 MYOBLOC
17 A Phase III, Prospective, Multicenter, Open-label Extension Study to Assess the Longer Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Cervical Dystonia Completed NCT00288509 Phase 3
18 Phase 3 Study of Vitamin D Analog (Alfacalcidol) on Muscle Strength in Elderly Indonesian Women Who Have Low Handgrip Strength Completed NCT02327091 Phase 3 alfacalcidol
19 Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis Completed NCT02207231 Phase 3 Guselkumab 100 mg;Placebo for guselkumab;Adalimumab;Placebo for adalimumab
20 A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine When Administrated in Healthy Subjects Aged 6 Months Through 47 Months Recruiting NCT03932682 Phase 3
21 Effect of Adjunctive Metformin on Recurrence of Non-DM Colorectal Cancer Stage II High-risk/ III Colorectal Cancer: Open-label Randomized Controlled Recruiting NCT02614339 Phase 3 metformin;control
22 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema Withdrawn NCT01882712 Phase 3 CD07805/47 Gel 0.5%;CD07805/47 Gel Placebo
23 The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark (Cinnamomum Verum and C. Aromaticum) (Cinnamonforceâ„¢) - Randomized Placebo-Controlled Clinical Trial Unknown status NCT00479973 Phase 2
24 Effect of CD07805/47 Gel in Subjects Presenting With Flushing Related to Erythematotelangiectatic or Papulopustular Rosacea Completed NCT02300129 Phase 2 CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo;Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo;CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47;Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47
25 A 4-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Investigating the Efficacy and Safety of CD07805/47 Gel 0.5% Applied Topically Once Daily (QD), and CD07805/47 Gel 0.18% Applied Topically Once Daily (QD) or Twice Daily (BID), in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01174030 Phase 2 CD07805/47 Gel;Vehicle Gel;CD07805/47 Gel;CD07805/47 Gel;Vehicle Gel
26 Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy Completed NCT01091974 Phase 2 armodafinil;Placebo Comparator
27 A Dbl-blind,Randomized,Controlled,Phase IIb Field Trial in 12-47 Month-old Children in Western Kenya to Eval the Efficacy,Safety and Immunogenicity of the FMP1/AS02A Malaria Vaccine vs Rabies Vaccine Completed NCT00223990 Phase 2
28 Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Dose-Finding Study Investigating the Pharmacodynamics and Safety of Three Concentrations of CD07805/47 Topical Gel (0.07%, 0.18%, and 0.50%), Applied in Subjects With Moderate to Severe Erythematotelangiectatic Rosacea Completed NCT00989014 Phase 2 CD07805/47;CD07805/47;CD07805/47;CD07805/47 placebo
29 Phase II Trial of Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer After Previous Local Therapy. Completed NCT00596895 Phase 2
30 A Phase II Trial to Assess the Activity of TroVax® Alone vs. TroVax® Plus Interferon Alfa (IFN-α) on Patients With Advanced or Metastatic Renal Cell Cancer Completed NCT00445523 Phase 2 Interferon-alpha
31 Double-blind, Placebo-controlled Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in Children Completed NCT01328925 Phase 2 Nitazoxanide
32 Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) in Patients With Metastatic or Recurrent Cancer of the Endometrium Completed NCT00249990 Phase 2 9-NC in aerosol reservoir
33 Eculizumab to Enable Renal Transplantation in Patients With History of Antiphospholipid Antibody Syndrome or Catastrophic Antiphospholipid Antibody Syndrome Completed NCT01029587 Phase 2 Eculizumab
34 Effect of Thermal Stimulation on Cortical Excitability and Motor Function in Chronic Stroke Patients Completed NCT01407536 Phase 1, Phase 2
35 Randomized Phase 2 Trial of Tirapazamine and the Role of Tumor Hypoxia in Advanced Squamous Head and Neck Cancer Completed NCT00002774 Phase 2 Tirapazamine;Cisplatin;5-fluorouracil
36 Phase II Trial of Neoadjuvant Chemoradiation With Bevacizumab for Chinese Locally Advanced Rectal Adenocarcinoma Completed NCT01554059 Phase 2 Bevacizumab;Oxaliplatin;5-FU
37 Randomized, Double-blind Placebo-controlled Multi-center Proof-of-concept Study to Assess the Efficacy of AIN457 in Patients With Psoriatic Arthritis Completed NCT00809614 Phase 2
38 Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Longkoma Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) Implanted in Populations of 6 Weeks and Older Recruiting NCT04563533 Phase 1, Phase 2
39 Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma Recruiting NCT03047928 Phase 1, Phase 2 Nivolumab
40 Phase I/II Trial of Anti-PD-1 Checkpoint Inhibitor Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer Active, not recruiting NCT03325816 Phase 1, Phase 2 Nivolumab
41 A Pilot Study of Low Dose IL-2 in the Treatment of Relapsing Polychondritis Not yet recruiting NCT04077736 Phase 2 Interleukin-2
42 Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica Not yet recruiting NCT04062006 Phase 2 Interleukin-2
43 A Phase II Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer (47-02-001) Terminated NCT00585416 Phase 2 CGC-11047
44 IntraCoronary Treatment With Integrilin To Improve ANgiographic Outcomes (IC TITAN - TIMI 47) Trial Terminated NCT00719914 Phase 2 eptifibatide;eptifibatide;normal saline
45 A Phase 1 Study to Evaluate the Pharmacokinetic Profile of ACH-0144471 Following Administration of Modified Release Prototype Formulations in Healthy Subjects Completed NCT03384186 Phase 1 ACH-0144471 Modified Release Prototype 1;ACH-0144471 Modified Release Prototype 2;ACH-0144471 Modified Release Prototype 3;ACH-0144471 Modified Release Prototype 4;ACH-0144471 Modified Release Prototype 5
46 Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group Trial to Assess the Potential Electrocardiographic Effects of Rotigotine Transdermal System up to 120 cm2/54.0 mg/Day in Subjects With Advanced-stage Idiopathic Parkinson's Disease: A Thorough QT/QTc Trial. Completed NCT00292227 Phase 1 Rotigotine;Moxifloxacin infusion
47 Double-blind,Randomized,Controlled,Dose Escalation Phase 1 Trial in 12-47 Month Old Children in Western Kenya to Evaluate the Safety and Immunogenicity of WRAIR's MSP-1(FMP1) Malaria Vaccine Adjuvanted in GSK's AS02A Versus Rabies Vaccine. Completed NCT00317473 Phase 1
48 A 47 Hour, Single Application, Occlusive Forearm Skin Patch Test to Assess, Under Dermatological Control, the Acute Cutaneous Tolerance of Project Storm on the Forearm of Adult Subjects With Dry/Atopic and Very Dry/Atopic Skin Completed NCT02620293 Phase 1
49 A Double-Blind, Randomized, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of V950 Formulated on Aluminum-Containing Adjuvant With or Without ISCOMATRIXâ„¢ in Patients With Alzheimer Disease Completed NCT00464334 Phase 1
50 A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignancies Recruiting NCT03717103 Phase 1 IBI188;IBI188;IBI188, Rituximab

Search NIH Clinical Center for Triple X Syndrome

Sources

Genetic Tests for Triple X Syndrome

About this section

Genetic tests related to Triple X Syndrome:

# Genetic test Affiliating Genes
1 Trisomy X Syndrome 29
Sources

Anatomical Context for Triple X Syndrome

About this section

MalaCards organs/tissues related to Triple X Syndrome:

40
Prostate, Skin, Kidney, Liver, Bone, Spinal Cord, Bone Marrow
Sources

Publications for Triple X Syndrome

About this section

Articles related to Triple X Syndrome:

(show top 50) (show all 109)
# Title Authors PMID Year
1
Social functioning and emotion recognition in adults with triple X syndrome. 61
33583482 2021
2
Chromosomal abnormality: Prevalence, prenatal diagnosis and associated anomalies based on a provincial-wide birth defects monitoring system. 61
33372274 2020
3
Evaluating the Scope of Language Impairments in a Patient with Triple X Syndrome: A Brief Report. 61
32419557 2020
4
Epigenetic and transcriptomic consequences of excess X-chromosome material in 47,XXX syndrome-A comparison with Turner syndrome and 46,XX females. 61
32489015 2020
5
The epidemiology of sex chromosome abnormalities. 61
32506765 2020
6
Cell-free DNA screening for sex chromosome aneuploidies by non-invasive prenatal testing in maternal plasma. 61
32190123 2020
7
Symptomatic Mandibular Fibrous Dysplasia With Concurrent Triple X- and Premutation Stage Fragile-X-Syndrome: Case Report With Short Literature Survey. 61
31810942 2019
8
47, XXX syndrome with infertility, premature ovarian insufficiency, and streak ovaries. 61
31183102 2019
9
Non-invasive prenatal testing for detection of trisomy 13, 18, 21 and sex chromosome aneuploidies in 8594 cases. 61
31165466 2019
10
Sex differences in psychiatric disorders: what we can learn from sex chromosome aneuploidies. 61
30127341 2019
11
Changes in the cohort composition of turner syndrome and severe non-diagnosis of Klinefelter, 47,XXX and 47,XYY syndrome: a nationwide cohort study. 61
30642344 2019
12
Identification of paternal uniparental disomy on chromosome 22 and a de novo deletion on chromosome 18 in individuals with orofacial clefts. 61
30141273 2018
13
Behavioral and psychological features in girls and women with triple-X syndrome. 61
30070765 2018
14
Novel biallelic ATM mutations coexist with a mosaic form of triple X syndrome in an 11-year-old girl at remission after T cell acute leukemia. 61
29492593 2018
15
Vocal and gestural productions of 24-month-old children with sex chromosome trisomies. 61
28726283 2018
16
Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women. 61
29125628 2017
17
Sex chromosome aneuploidies and copy-number variants: a further explanation for neurodevelopmental prognosis variability? 61
28612834 2017
18
Generation of integration-free induced pluripotent stem cells (GZHMUi001-A) by reprogramming peripheral blood mononuclear cells from a 47, XXX syndrome patient. 61
28925367 2017
19
A finding in genetic polymorphism analysis study: A case of non-mosaic 47, XXX without manifestations. 61
28697408 2017
20
Detection of Turner syndrome using X-chromosome inactivation specific differentially methylated CpG sites: A pilot study. 61
28284085 2017
21
Noninvasive prenatal screening for fetal common sex chromosome aneuploidies from maternal blood. 61
28357876 2017
22
Cross-sectional study shows that impaired bone mineral status and metabolism are found in nonmosaic triple X syndrome. 61
28090675 2017
23
Gender balance in patients with systemic lupus erythematosus. 61
28137478 2017
24
Expanding the phenotype of Triple X syndrome: A comparison of prenatal versus postnatal diagnosis. 61
27644018 2016
25
Triple X syndrome and puberty: focus on the hypothalamus-hypophysis-gonad axis. 61
26952785 2016
26
High Myopia Associated with Triple X Syndrome. 61
27928398 2016
27
Cytogenetic studies of 1232 patients with different sexual development abnormalities from the Sultanate of Oman. 61
26706459 2016
28
Over-expression of XIST, the Master Gene for X Chromosome Inactivation, in Females With Major Affective Disorders. 61
26425698 2015
29
The Turner syndrome in patient with 45X/47XXX mosaic karyotype--case report. 61
25826153 2015
30
45,X/47,XXX Mosaicism and Short Stature. 61
26137340 2015
31
A case-control study of brain structure and behavioral characteristics in 47,XXX syndrome. 61
25287572 2014
32
Bladder exstrophy-epispadias complex and triple-X syndrome: incidental finding or causality? 61
25200913 2014
33
Structural and numerical changes of chromosome X in patients with esophageal atresia. 61
24398799 2014
34
A case associated with comorbidities among cerebral infarction, idiopathic thrombocytopenic purpura, and triple x syndrome. 61
25035678 2014
35
Craniofacial and dental manifestations of triple X syndrome associated with congenital hypothyroidism: a case report. 61
24117978 2014
36
Poor socio-economic status in 47,XXX --an unexpected effect of an extra X chromosome. 61
23542668 2013
37
Cytogenetic evaluation of patients with clinical spectrum of Turner syndrome. 61
24082654 2013
38
Fetal axillary cystic hygroma: a novel association with triple X syndrome. 61
23109196 2012
39
Triple x syndrome with short stature: case report and literature review. 61
23056899 2012
40
Mosaic triple X syndrome in a female with primary amenorrhea. 61
23162306 2012
41
Autism in association with Triple X syndrome. 61
22311144 2012
42
Triple X syndrome. 61
22755288 2012
43
The psychiatric phenotype in triple X syndrome: new hypotheses illustrated in two cases. 61
22582855 2012
44
Gilles de la Tourette's syndrome in a patient with 47(XXX) syndrome: a case report. 61
22054059 2011
45
Premature ovarian aging in primary infertility: Triple X syndrome. 61
22346085 2011
46
GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings. 61
21497194 2011
47
Application of microsatellite loci on the chromosome X for rapid prenatal detection of the chromosome X numerical abnormalities. 61
21674836 2011
48
Maternal de novo triple mosaicism for two single OCRL nucleotide substitutions (c.1736A>T, c.1736A>G) in a Lowe syndrome family. 61
21225285 2011
49
Triple X syndrome: characteristics of 42 Italian girls and parental emotional response to prenatal diagnosis. 61
20473517 2010
50
Human embryonic stem cells as models for aneuploid chromosomal syndromes. 61
20641042 2010
Sources

Variations for Triple X Syndrome

About this section
Sources

Expression for Triple X Syndrome

About this section
Search GEO for disease gene expression data for Triple X Syndrome.
Sources

Pathways for Triple X Syndrome

About this section
Sources

GO Terms for Triple X Syndrome

About this section
Sources

Sources for Triple X Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....